GLP-1 drugs linked to lower risk of serious fractures in older diabetics

A study published in JAMA Network Open has found that GLP-1 medications may reduce the risk of serious fractures in older adults with type 2 diabetes.

Researchers reviewed medical data from around 134,000 diabetes patients in the United States, aged between 50 and 90, comparing those who began taking GLP-1 drugs with those using DPP-4 inhibitors.

Over three years of follow-up, the researchers observed a nearly 21% reduction in the risk of fractures caused by minor injuries among GLP-1 users, with the greatest decrease seen in hip, thigh, and spinal fractures.

The scientists noted that doctors had previously feared rapid weight loss from these drugs might weaken bones, but the study's results showed the opposite.

However, the researchers emphasized that the study was observational and does not prove a direct protective effect of GLP-1 drugs on bone tissue.

Some doctors cautioned that these medications could pose risks for patients with amyotrophic lateral sclerosis (ALS), as their mechanism relies on rapid weight loss, which may not be suitable for those with neuromuscular disorders.

A recent study also indicated that GLP-1 drugs used for type 2 diabetes and obesity may be linked to an increased risk of hair loss (alopecia).

Additionally, a scientific review found that weight-loss medications do not significantly improve users' quality of life, and their benefits may be accompanied by side effects that require weighing risks and rewards before starting treatment.